DOCSLIB.ORG

( 12 ) Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0159509 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
( 12 ) Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0159509 A1 US 20190159509A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0159509 A1 Cameron et al. (43 ) Pub . Date : May 30 , 2019 (54 ) WATER -BASED VAPORIZABLE LIQUIDS , A24F 47 /00 (2006 .01 ) METHODS AND SYSTEMS FOR A61M 15 / 00 (2006 .01 ) VAPORIZING SAME A61M 11/ 04 ( 2006 .01 ) A61K 31/ 522 ( 2006 .01 ) ( 71 ) Applicant: Lunatech , LLC , Studio City , CA (US ) A61M 15 / 06 ( 2006 . 01 ) A61K 47 / 10 ( 2006 .01 ) ( 72 ) Inventors : John David Cameron , Studio City , CA A61K 31/ 465 (2006 . 01 ) ( US ) ; Dean Becker , Fairhope , AL (US ) ; A61K 9 / 08 (2006 . 01 ) Gene Fein , Oxnard , CA (US ) ( 52) U . S . CI. CPC .. .. .. A24B 15 / 167 (2016 . 11 ) ; A61K 9 /007 (21 ) Appl. No . : 16 / 265 ,637 ( 2013 .01 ) ; A24F 47 / 008 ( 2013 . 01 ) ; A61M 15 / 0085 ( 2013 .01 ) ; A61M 11 /042 ( 2014 .02 ) ; (22 ) Filed : Feb . 1 , 2019 A61M 2016 / 0039 ( 2013 .01 ) ; A61M 15 / 06 Related U . S . Application Data ( 2013 .01 ) ; A61K 47 / 10 ( 2013 .01 ) ; A61K 31/ 465 ( 2013 .01 ) ; A61K 9 / 08 ( 2013 .01 ) ; A61K (63 ) Continuation of application No . 15 / 338 ,519 , filed on 31 / 522 ( 2013 . 01) Oct. 31, 2016 , Continuation of application No . 16 / 203 , 447 , filed on Nov . 28 , 2018 , said application No. 15 /338 ,519 is a continuation of application No . ( 57 ) ABSTRACT 15 / 337 , 341, filed on Oct. 28 , 2016 , now abandoned . ( 60 ) Provisional application No . 62 /249 , 114 , filed on Oct . Provided are systems, methods , and liquids related to elec 30 , 2015 . tronic vapor devices. In one aspect , the application relates to a water- based vaporizable liquid for use in the systems, Publication Classification methods and electronic vapor devices . This abstract is (51 ) Int. CI. intended as a scanning tool for purposes of searching in the A24B 15 / 16 ( 2006 .01 ) particular art and is not intended to be limiting of the present A61K 9 / 00 ( 2006 .01 ) invention . VAPOR OUTPUT 228 226 15224- 224 2 12 - - - - - - - - - - - 21 222 214 202 22 218 220 1206 2104 204 208 230 232 Patent Application Publication May 30 , 2019 Sheet 1 of 4 US 2019 / 0159509 A1 FIG . 1 100 Processor GPS 102 118 . .,' Memory Device 104 Network Power Supply Access 120 Device 106 Container Input/ Output 110 112 Vaporizer Flow Sensor 208222222222222222.02201209 108 116 Outlet 114 00000D Patent Application Publication May 30 , 2019 Sheet 2 of 4 US 2019 / 0159509 A1 FIG . 2 VAPOR OUTPUT 200 228 226 | - - 224224 WANAW - N www . N . N . OWwWwwWw . ama DDD 216 RRRRRRRRRRRRRRRRR . .. .. 206 . 208 232 : : : : : : : : . .. .. : . : . : : . : : . : . : : : . :. : . : . DARM R0. HRUARDOORLD . O . O O O . O . O . R OO . AHHAHARLARDI . Patent Application Publication May 30 , 2019 Sheet 3 of 4 US 2019 / 0159509 A1 FIG . 3 - 224 214 202 . 907 .1 230 Patent Application Publication May 30 , 2019 Sheet 4 of 4 US 2019 / 0159509 A1 FIG . 4 . 402 . Receive a water- based vaporizablewww. liquid 404 . eininnissa . ALATASARATILADI . DisperseWww the water -based vaporizable liquid , resulting in a substantiallyWW invisible vapor SAN 406 * * * WWWWWWWWWWWWW. XXWWW. WWWWWWWWWWWWWWWWWW Expel the substantially invisible vapor though an exhaust port #IRANASLANIRANIN I 2 91 + * + - + * 1 * 22222 2 2 . 1 + 1 + 1 + 1 + 1 + 1 . 22 . 2 .2 22 . 22 . 1 + 1 + 1 + 1 . US 2019 /0159509 A1 May 30 , 2019 WATER -BASED VAPORIZABLE LIQUIDS , composition , a nutraceutical composition , and a plant METHODS AND SYSTEMS FOR extract , wherein the vaporizable liquid composition is sub VAPORIZING SAME stantially free of propylene glycol (PG ) and vegetable glyc erin (VG ) . CROSS -REFERENCE TO RELATED [ 0007 ] Also disclosed are methods for preparing the dis APPLICATIONS closed vaporizable liquids can comprise the step of com [0001 ] This Application claims the benefit of U . S . Non bining a solvent and at least one agent selected from a Provisional patent application Ser. No . 16 / 203 , 447, filed on pharmaceutical composition , a nutraceutical composition , Nov. 28, 2018 , which claims the benefit of U . S . Non and plant extract , to thereby provide a vaporizable liquid . Provisional patent application Ser. No . 15 / 338 ,519 , filed on The vaporizable liquid is substantially free of propylene Oct. 31, 2016 , which claims the benefit of U . S . Non glycol ( PG ) vegetable glycerin (VG ). Provisional patent application Ser . No . 15 / 337 ,341 , filed on [0008 ] In another aspect, an exemplary system can com Oct. 28 , 2016 and U . S . Provisional Patent Application No . prise a dispersion element configured to disperse the dis 62 / 249, 114 , filed on Oct . 30 , 2015, which are incorporated closed vaporizable liquids to form a vapor or mist such that herein by reference in their entirety . vapor or mist emitted from the device comprises a substan tially invisible vapor trail . BACKGROUND [0009 ] In another aspect , an example method can com [0002 ] Consumers utilize electronic vapor cigarettes, prise receiving a disclosed vaporizable liquids at a disper pipes , and modified vapor devices to enjoy what is com sion element and causing the water- based vaporizable liquid monly known as “ vaping. ” Vaping is an increasingly popular to disperse , resulting in a vapor or mist . The methods further market segment , which has been , and continues to be , can comprise expelling the vapor or mist through an exhaust steadily gainingmarket share over the last several years . The port for inhalation by a user . The vapor or mist can be fluid utilized for vaping within some electronic vapor substantially invisible . devices is commonly known as “ eJuice .” The eJuice cur [0010 ] Still other objects and advantages of the present rently utilized in the vaping market contains at least one of disclosure will become readily apparent by those skilled in propylene glycol (PG ) and vegetable glycerin ( VG ) . In fact, the art from the following detailed description , wherein it is a majority of the liquid contained in an e Juice cartridge , shown and described only the preferred aspects , simply by chamber, soaked batting system , or other receptacle for way of illustration of the best mode . As will be realized , the eJuice is made up of one or both of PG and / or VG . The PG disclosure is capable of other and different aspects , and its and / or VG are largely responsible for the vapor plume several details are capable of modifications in various obvi created by the vaporized eJuice inhaled and exhaled by ous respects , without departing from the disclosure. Accord users . Some users do not enjoy the ‘ vapor cloud created by ingly , the description is to be regarded as illustrative in using eJuice containing PG and /or VG in vapor devices. nature and not as restrictive . Further, there are consequences associated with the vapor cloud produced by PG and /or VG . Namely, the vapor cloud BRIEF DESCRIPTION OF THE DRAWINGS is an annoyance to many non - vapor users which has trig gered subsequent banning of vaping in certain designated [0011 ] The features , nature , and advantages of the present areas , such as restaurants , workplaces etc . Additionally , disclosure will become more apparent from the detailed utilizing vapor devices with PG and / or VG creates a large description set forth below when taken in conjunction with amount of wasted fluid as much of the vapor ends up not the drawings , in which like reference characters are used to absorbed and exhaled into the air . identify like elements correspondingly throughout the speci [ 0003 ] Despite the widespread population of vaping , fication and drawings . e Juice that is substantially free from PG and VG has [0012 ] FIG . 1 shows a representative block diagram of an remained elusive . Thus , there remains a need for vaporizable electronic vapor device configured for vaporizing a water liquid that produces a substantially invisible vapor cloud and based vaporizable liquid . methods ofmaking and using same. These needs and others [ 0013 ] FIG . 2 shows a representative illustration of a are met by the present invention . vapor device configured for vaporizing a water - based vapor izable liquid . SUMMARY [0014 ] FIG . 3 shows a representative illustration of the [ 0004 ] In accordance with the purpose( s ) of the invention , vapor device configured for vaporizing water -based vapor as embodied and broadly described herein , the invention , in izable liquid , as shown in FIG . 2 . one aspect, relates to vaporizable liquids useful for vaping . [ 0015 ] FIG . 4 shows a representative illustration of a [0005 ] Thus, disclosed are vaporizable liquids which are method for vaporizing a water -based vaporizable liquid . substantially free of propylene glycol (PG ) vegetable glyc [ 0016 ] Additional advantages of the invention will be set erin (VG ) , systems and methods for making and using the forth in part in the description which follows, and in part will disclosed vaporizable liquids . An exemplary vaporizable be obvious from the description , or can be learned by liquid can comprise at least one solvent and at least one practice of the invention . The advantages of the invention agent selected from a pharmaceutical composition , a nutra will be realized and attained by means of the elements and ceutical composition , and plant extract. combinations particularly pointed out in the appended [0006 ] Also disclosed are vaporizable liquid compositions claims. It is to be understood that both the foregoing general comprising: ( a ) at least one solvent comprising water , a description and the following detailed description are exem water -based solution , an alcohol, or a combination thereof; plary and explanatory only and are not restrictive of the and ( b ) at least one agent selected from a pharmaceutical invention , as claimed . US 2019 /0159509 A1 May 30 , 2019 DETAILED DESCRIPTION programmable apparatus provide steps for implementing the functions specified in the flowchart block or blocks . [ 0017 ] The present invention can be understood more [0023 ] Accordingly , blocks of the block diagrams and readily by reference to the following detailed description of flowchart illustrations support combinations of means for the invention and the Examples included therein .
Load more

Recommended publications
  • Commission Implementing Regulation (EU)
    21.3.2013 EN Official Journal of the European Union L 80/1 II (Non-legislative acts) REGULATIONS COMMISSION IMPLEMENTING REGULATION (EU) No 230/2013 of 14 March 2013 on the withdrawal from the market of certain feed additives belonging to the group of flavouring and appetising substances (Text with EEA relevance) THE EUROPEAN COMMISSION, submitted before that deadline for the only animal category for which those feed additives had been auth­ orised pursuant to Directive 70/524/EEC. Having regard to the Treaty on the Functioning of the European Union, (4) For transparency purposes, feed additives for which no applications for authorisation were submitted within the Having regard to Regulation (EC) No 1831/2003 of the period specified in Article 10(2) of Regulation (EC) No European Parliament and of the Council of 22 September 1831/2003 were listed in a separate part of the 2003 on additives for use in animal nutrition ( 1 ), and in Community Register of Feed Additives. particular Article 10(5) thereof, (5) Those feed additives should therefore be withdrawn from Whereas: the market as far as their use as flavouring and appetising substances is concerned, except for animal species and categories of animal species for which applications for (1) Regulation (EC) No 1831/2003 provides for the auth­ authorisation have been submitted. This measure does orisation of additives for use in animal nutrition and not interfere with the use of some of the abovemen­ for the grounds and procedures for granting such auth­ tioned additives according to other animal species or orisation. Article 10 of that Regulation provides for the categories of animal species or to other functional re-evaluation of additives authorised pursuant to Council groups for which they may be allowed.
    [Show full text]
  • Test Items for Licensing Examination Krok 1 PHARMACY
    MINISTRY OF PUBLIC HEALTH OF UKRAINE Department of human resources policy, education and science Testing Board Student ID Last name Variant ________________ Test items for licensing examination Krok 1 PHARMACY (російськомовний варіант) General Instruction Every one of these numbered questions or unfinished statements in this chapter corresponds to answers or statements endings. Choose the answer (finished statements) that fits best and fill in the circle with the corresponding Latin letter on the answer sheet. Authors of items: Abramov A.V., Aleksandrova K.V., Andronov D.Yu., Bilyk O.V., Blinder O.O., Bobyr V.V., Bobrovska O.A., Bohatyriova O.V., Bodnarchuk O.V., Boieva S.S., Bolokhovska T.O., Bondarenko Yu.I., Bratenko M.K., Buchko O.V., Cherneha H.V., Davydova N.V., Deriuhina L.I., Didenko N.O., Dmytriv A.M., Doroshkevych I.O., Dutka N.M., Dynnyk K.V., Filipova L.O., Havryliuk I.M., Herhel T.M., Hlushkova O.M., Hozhdzinsky S.M., Hrekova T.A., Hrechana O.V., Hruzevsky O.A., Hudyvok Ya.S., Hurmak I.S., Ivanets L.M., Ivanov Ye.I., Kartashova T.V., Kava T.V., Kazakova V.V., Kazmirchuk H.V., Kernychna I.Z., Khlus K.M., Khmelnykova L.I., Klebansky Ye.O., Klopotsky H.A., Klymniuk S.I., Kobylinska L.I., Koldunov V.V., Kolesnyk V.P., Kolesnikova T.O., Komlevoy O.M., Kononenko N.M., Kornijevsky Yu.Y., Kremenska L.V., Krushynska T.Yu., Kryzhanovska A.V., Kryshtal M.V., Kukurychkin Ye.R., Kuznietsova N.L., Kuzmina A.V., Lisnycha A.M., Lychko V.H., Makats Ye.F., Maly V.V., Matvijenko A.H., Menchuk K.M., Minarchenko V.M., Mikheiev A.O., Mishchenko
    [Show full text]
  • 56 Subpart F—Flavoring Agents and Related Substances
    § 172.510 21 CFR Ch. I (4–1–12 Edition) needed to produce its intended effect (a) They are used in the minimum but not in excess of 13 parts per million quantity required to produce their in- calculated as anhydrous sodium ferro- tended physical or technical effect and cyanide. in accordance with all the principles of [42 FR 14491, Mar. 15, 1977, as amended at 58 good manufacturing practice. FR 17098, Apr. 1, 1993] (b) In the appropriate forms (plant parts, fluid and solid extracts, con- Subpart F—Flavoring Agents and centrates, absolutes, oils, gums, bal- Related Substances sams, resins, oleoresins, waxes, and dis- tillates) they consist of one or more of § 172.510 Natural flavoring substances the following, used alone or in com- and natural substances used in con- bination with flavoring substances and junction with flavors. adjuvants generally recognized as safe Natural flavoring substances and in food, previously sanctioned for such natural adjuvants may be safely used use, or regulated in any section of this in food in accordance with the fol- part. lowing conditions. Common name Scientific name Limitations Aloe ................................................................ Aloe perryi Baker, A. barbadensis Mill., A. ferox Mill., and hybrids of this sp. with A. africana Mill. and A. spicata Baker. Althea root and flowers .................................. Althea officinalis L. Amyris (West Indian sandalwood) ................. Amyris balsamifera L. Angola weed .................................................. Roccella fuciformis
    [Show full text]
  • RIFM Fragrance Ingredient Safety Assessment, Menthyl Isovalerate CAS Registry Number 16409-46-4
    Food and Chemical Toxicology 110 (2017) S486eS495 Contents lists available at ScienceDirect Food and Chemical Toxicology journal homepage: www.elsevier.com/locate/foodchemtox Short review RIFM fragrance ingredient safety assessment, menthyl isovalerate CAS Registry Number 16409-46-4 * A.M. Api a, , D. Belsito b, D. Botelho a, D. Browne a, M. Bruze c, G.A. Burton Jr. d, J. Buschmann e, M.L. Dagli f, M. Date a, W. Dekant g, C. Deodhar a, M. Francis a, A.D. Fryer h, K. Joshi a,S.LaCavaa, A. Lapczynski a, D.C. Liebler i, D. O'Brien a, R. Parakhia a,A.Patela, T.M. Penning j, G. Ritacco a, J. Romine a, D. Salvito a, T.W. Schultz k, I.G. Sipes l, Y. Thakkar a, E.H. Theophilus a, A.K. Tiethof a, Y. Tokura m, S. Tsang a, J. Wahler a a Research Institute for Fragrance Materials, Inc., 50 Tice Boulevard, Woodcliff Lake, NJ 07677, USA b Member RIFM Expert Panel, Columbia University Medical Center, Department of Dermatology, 161 Fort Washington Ave., New York, NY 10032, USA c Member RIFM Expert Panel, Malmo University Hospital, Department of Occupational & Environmental Dermatology, Sodra Forstadsgatan 101, Entrance 47, Malmo SE-20502, Sweden d Member RIFM Expert Panel, School of Natural Resources & Environment, University of Michigan, Dana Building G110, 440 Church St., Ann Arbor, MI 58109, USA e Member RIFM Expert Panel, Fraunhofer Institute for Toxicology and Experimental Medicine, Nikolai-Fuchs-Strasse 1, 30625 Hannover, Germany f Member RIFM Expert Panel, University of Sao Paulo, School of Veterinary Medicine and Animal Science, Department of Pathology, Av.
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,265,155 B2 Artman Et A1
    US007265155B2 (12) United States Patent (10) Patent N0.: US 7,265,155 B2 Artman et a1. (45) Date of Patent: *Sep. 4, 2007 (54) TREATING A VARIETY OF PATHOLOGICAL W0 98 08498 A 3/1998 CONDITIONS, INCLUDING SPASTICITY WO WO98/08498 3/1998 AND CONVULSIONS, BY EFFECTING A WO WO99/44623 3/1999 MODULATION OF CNS ACTIVITY WITH W0 WO 01/28516 10/2000 ISOVALERAMIDE, ISOVALERIC ACID, OR A RELATED COMPOUND OTHER PUBLICATIONS Schon and Blau, J Neurol Neurosurg Psychiatry, Sep. 1987: (75) Inventors: Linda D. Artman, Salt Lake City, UT 50(9):1148-1152.* (US); Manuel Balandrin, Sandy, UT Dorland’s Medical Dictionary 27th ed. p. 379* (US); Robert L. Smith, Lansdale, PA Pharmacotherapy, A Pathophysiologic Approach, Dipiro et al.2nd (Us) ed. 1991, pp. 1232, 1238).* Drug facts and comparisons 1999 ed. pp. 1595-1597(“Drug (73) Assignee: NBS Pharmaceuticals, Inc., Salt Lake Facts”).* City, UT (US) Pharmacotherapy, A Pathophysiologic Approach, Dipiro et al. 2nd ed. 1991, pp. 1232 & 1238* Notice: Subject to any disclaimer, the term of this Drug Facts and Comparisons. 1999 ed. pp. 1595-1597 (“Drug patent is extended or adjusted under 35 Facts”).* Julius A. Vida “Advances in Anticonvulsant Drug Development”; USC 154(b) by 0 days. Anticonvulsants (1997) pp. 1-9; Academic Press. Julius A. Vida “Noncyclic Anticonvulsants”; Anticonvulsants This patent is subject to a terminal dis (1977) pp. 577-619; Academic Press. claimer. Salim Hadad, et al. “Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Deriatives of GABA and Glycine”; Phar (21) Appl. N0.: 10/614,344 maceutical Research (1995), pp. 905-907; Plenum Publishing Cor poration.
    [Show full text]
  • Cigarette Additives, Carcinogens and Chemicals Nicotine
    Cigarette Additives, Carcinogens and Chemicals Nicotine A Destructive Natural Pesticide Which ... Is extremely addictive when smoked Is extremely addictive when chewed Causes addiction as permanent as Is harder to quit than heroin or cocaine alcoholism Is not medicine and its use not therapy Is ineffective as a stand-alone quitting aid Prevents pre-cancerous cells from dying Accelerates cancer tumor growth rates Contributes to artery hardening Has a metabolite which may cause cancer May kill brain cells and impair memory Is linked to lung cancer Likely causes brain damage and Is also a fetus destroying teratogen depression Kills half of adult smokers 13-14 years Is beat by never taking another puff or early chew! 81 Cancer Causing Chemicals Have So Far Been Identified in Cigarettes Acetaldehyde Acetamide Acrylamide Acrylonitrile 2-Amino-3,4-dimethyl-3H-imidazo[4,5-f]quinoline (MeIQ) 3-Amino-1,4-dimethyl-5H-pyrido [4,3-b]indole (Trp-P-1) 2-Amino-l-methyl-6-phenyl-1H-imidazo [4,5-b]pyridine (PhlP) 2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole (Glu-P-1) 3-Amino-l-methyl-5H-pyrido {4,3-b]indole (Trp-P-2 2-Amino-3-methyl-9H-pyrido[2,3-b]indole (MeAaC) 2-Amino-9H-pyrido[2,3-b]indole (AaC) 4-Aminobiphenyl 2-Aminodipyrido[1,2-a:3',2'-d]imidazole (Glu-P-2) 0-Anisidine Arsenic Benz[a]anthracene Benzene Benzo[a]pyrene Benzo[b]fluoranthene Benzo[j]fluoranthene Benzo[k]fluoranthene Benzo[b]furan Beryllium 1,3-Butadiene Cadmium Catechol (1,2-benzenediol) p-Chloroaniline Chloroform Cobalt p,p'-DDT Dibenz[a,h]acridine Dibenz[a,j]acridine Dibenz(a,h)anthracene
    [Show full text]
  • Cover Next Page > Cover Next Page >
    cover next page > Cover title: The Psychopharmacology of Herbal Medicine : Plant Drugs That Alter Mind, Brain, and Behavior author: Spinella, Marcello. publisher: MIT Press isbn10 | asin: 0262692651 print isbn13: 9780262692656 ebook isbn13: 9780585386645 language: English subject Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. publication date: 2001 lcc: RC483.S65 2001eb ddc: 615/.788 subject: Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. cover next page > < previous page page_i next page > Page i The Psychopharmacology of Herbal Medicine < previous page page_i next page > cover next page > Cover title: The Psychopharmacology of Herbal Medicine : Plant Drugs That Alter Mind, Brain, and Behavior author: Spinella, Marcello. publisher: MIT Press isbn10 | asin: 0262692651 print isbn13: 9780262692656 ebook isbn13: 9780585386645 language: English subject Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. publication date: 2001 lcc: RC483.S65 2001eb ddc: 615/.788 subject: Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. cover next page > < previous page page_ii next page > Page ii This page intentionally left blank. < previous page page_ii next page > < previous page page_iii next page > Page iii The Psychopharmacology of Herbal Medicine Plant Drugs That Alter Mind, Brain, and Behavior Marcello Spinella < previous page page_iii next page > < previous page page_iv next page > Page iv © 2001 Massachusetts Institute of Technology All rights reserved. No part of this book may be reproduced in any form by any electronic or mechanical means (including photocopying, recording, or information storage and retrieval) without permission in writing from the publisher. This book was set in Adobe Sabon in QuarkXPress by Asco Typesetters, Hong Kong and was printed and bound in the United States of America.
    [Show full text]
  • Food and Drug Administration, HHS § 172.515
    Food and Drug Administration, HHS § 172.515 Common name Scientific name Limitations Rhubarb, garden root ..................................... Rheum rhaponticum L ................................................ Do. Rhubarb root .................................................. Rheum officinale Baill., R. palmatum L., or other spp. (excepting R. rhaponticum L.) or hybrids of Rheum grown in China. Roselle ........................................................... Hibiscus sabdariffa L .................................................. Do. Rosin (colophony) .......................................... Pinus palustris Mill., and other Pinus spp .................. Do. St. Johnswort leaves, flowers, and caulis ...... Hypericum perforatum L ............................................. Hypericin-free alcohol dis- tillate form only; in alco- holic beverages only Sandalwood, white (yellow, or East Indian) ... Santalum album L. Sandarac ........................................................ Tetraclinis articulata (Vahl.), Mast .............................. In alcoholic beverages only Sarsaparilla ..................................................... Smilax aristolochiaefolia Mill., (Mexican sarsaparilla), S. regelii Killip et Morton (Honduras sarsaparilla), S. febrifuga Kunth (Ecuadorean sarsaparilla), or undetermined Smilax spp. (Ecuadorean or Central American sarsaparilla). Sassafras leaves ............................................ Sassafras albidum (Nutt.) Nees ................................. Safrole free Senna, Alexandria .........................................
    [Show full text]
  • 7 Príloha Č. 1 K Tretej Hlave Druhej Časti Potravinového Kódexu
    Príloha č. 1 k tretej hlave druhej časti potravinového kódexu Kontaminanty v potravinách Časť A Chemické prvky 1. Chemické prvky v potravinách sú prvky, ktoré sa dostávajú do potravín z pôdy, vody a z ovzdušia ako kontaminanty; niektoré z nich môžu byť aj prirodzenou zložkou potravín. Pri posudzovaní ich zisteného množstva v potravinách nie je rozhodujúci spôsob, akým sa do potravín dostali a či sa vyskytujú v čistej forme alebo v zlúčeninách. Na posudzovanie rádionuklidov v potravinách sa vzťahujú osobitné požiadavky podľa šiestej hlavy druhej časti potravinového kódexu. 2. Najvyššie prípustné množstvo chemických prvkov vo výrobkoch na dojčenskú a detskú výživu sa vzťahuje na ich konzumnú formu podľa ich odporúčaného najmenšieho zriedenia. 3. Ak sú ryby určené celé na konzum, najvyššie prípustné množstvo sa vzťahuje na celé ryby. Chemický Najvyššie prípustné Potravina prvok množstvo v mg.kg-1 Arzén 0,05 mlieko, potraviny pre dojčatá a malé deti na báze mlieka 0,1 mäso a mäsové výrobky, múka, vajcia a výrob- ky z vajec, rastlinné tuky a oleje a živočíšne tuky, potraviny pre dojčatá a malé deti na ovocnom a zeleninovom základe 0,2 zverina a výrobky z nej, obilie a výrobky z neho, ocot, nápoje vrátane nápojov z ovocia a zeleniny, výrobky z mlieka okrem tvrdých syrov 0,3 zemiaky 0,5 tvrdé syry, ovocie a zelenina a výrobky z nich, strukoviny, čerstvé huby, čokoláda a výrobky z čo- kolády 1,0 vnútornosti a výrobky z nich, ryby sladkovodné a výrobky z nich, cukor a ostatné prírodné sladidlá okrem práškového cukru, cukrovinky, kakaový prášok
    [Show full text]
  • WO 2017/120012 Al 13 July 20 17 (13.07.2017) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/120012 Al 13 July 20 17 (13.07.2017) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/185 (2006.01) A61K 31/336 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US20 16/067024 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 15 December 2016 (15. 12.2016) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/275,182 5 January 2016 (05.01 .2016) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: THE REGENTS OF THE UNIVERSITY kind of regional protection available): ARIPO (BW, GH, OF CALIFORNIA [US/US]; 1111 Franklin Street, 12th GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Floor, Oakland, California 94607-5200 (US).
    [Show full text]
  • Wo 2009/120182 A2
    (12) INTERNATIONALAPPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 October 2009 (01.10.2009) WO 2009/120182 A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 47/34 (2006.01) CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, PCT/US2008/013816 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, 18 December 2008 (18.12.2008) NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, (25) Filing Language: English UG, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/015,365 20 December 2007 (20.12.2007) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 12/262,986 31 October 2008 (3 1.10.2008) US ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, (71) Applicant: EASTMAN CHEMICAL COMPANY [US/ ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, US]; 200 South Wilcox Drive, Kingsport, TN 37660 MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (US).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0096418 A1 Patron Et Al
    US 201700 96418A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0096418 A1 Patron et al. (43) Pub. Date: Apr. 6, 2017 (54) COMPOUNDS USEFUL AS MODULATORS Related U.S. Application Data OF TRPM8 (60) Provisional application No. 62/236,080, filed on Oct. (71) Applicant: Senomyx, Inc., San Diego, CA (US) 1, 2015. (72) Inventors: Andrew P. Patron, San Marcos, CA Publication Classification (US); Alain Noncovich, San Diego, CA (51) Int. Cl. (US); Jane Ung, San Diego, CA (US); C07D 409/2 (2006.01) Timothy Davis, Santee, CA (US); A6IR 9/00 (2006.01) Joseph R. Fotsing, San Diego, CA A63L/455 (2006.01) (US); Chad Priest, Leucadia, CA (US); (52) U.S. Cl. Catherine Tachdjian, San Diego, CA CPC ........ C07D 409/12 (2013.01); A61K 31/4155 (US) (2013.01); A61K 9/0014 (2013.01) (21) Appl. No.: 15/282,432 (57) ABSTRACT The present disclosure relates to compounds which are (22) Filed: Sep. 30, 2016 useful as cooling sensation compounds. US 2017/0096418 A1 Apr. 6, 2017 COMPOUNDS USEFUL AS MODULATORS -continued OF TRPM8 RELATED APPLICATIONS 0001. This application claims the benefit of U.S. Provi sional Application No. 62/236,080, filed Oct. 1, 2015, which is incorporated herein by reference in its entirety. BACKGROUND 0002 Field 0003. The present invention relates to compounds useful as cooling agents. 0004 Background Description 0005 Modulators of the Melastatin Transient Receptor or a salt or solvate thereof. Potential Channel 8 (TRPM8) are known to have a cooling effect. TRPM8 is a channel involved in the chemesthetic O008) In some embodiments the compound can have the sensation, such as cool to cold temperatures as well as the Structure sensation of known cooling agents.
    [Show full text]